Mobile

A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...

Update Il y a 5 ans
Reference: EUCTR2009-013256-69

A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate that QVA149 (110/50 μg o.d.) is superior to NVA237 (50 μg o.d.) with regard to the rate of moderate to severe COPD exacerbations during 52 weeks of treatment.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease (COPD)

Links